BR112016024214B8 - Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal - Google Patents

Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal

Info

Publication number
BR112016024214B8
BR112016024214B8 BR112016024214A BR112016024214A BR112016024214B8 BR 112016024214 B8 BR112016024214 B8 BR 112016024214B8 BR 112016024214 A BR112016024214 A BR 112016024214A BR 112016024214 A BR112016024214 A BR 112016024214A BR 112016024214 B8 BR112016024214 B8 BR 112016024214B8
Authority
BR
Brazil
Prior art keywords
monoclonal antibody
mabs
fragments
pharmaceutical composition
partially humanized
Prior art date
Application number
BR112016024214A
Other languages
English (en)
Other versions
BR112016024214A2 (pt
BR112016024214B1 (pt
Inventor
Ying Eng Jing
Julia Abdullah
Kate Rittenhouse-Olson
T Koury Stephen
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of BR112016024214A2 publication Critical patent/BR112016024214A2/pt
Publication of BR112016024214B1 publication Critical patent/BR112016024214B1/pt
Publication of BR112016024214B8 publication Critical patent/BR112016024214B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

anticorpos antigênicos anti-tf humanizados. são fornecidos anticorpos monoclonais (mabs) humanizados ou fragmentos dos mesmos que se ligam com especificidade ao antígeno de tumor humano de thomsen-friedenreich (tf). três cadeias pesadas variáveis e três leves variáveis distintas são fornecidas, e podem ser combinadas para fabricar um total de vinte e cinco combinações de cadeia pesada e leve distintas. métodos de usar os mabs e fragmentos dos mesmos para a terapia contra o câncer e imageamento de diagnóstico são fornecidos, como o são os métodos para fabricar os mabs e fragmentos dos mesmos. culturas de célula in vitro que expressam os mabs e fragmentos dos mesmos, e kits também são fornecidos.
BR112016024214A 2014-04-18 2015-04-20 Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal BR112016024214B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461981240P 2014-04-18 2014-04-18
US61/981,240 2014-04-18
PCT/US2015/026595 WO2015161311A2 (en) 2014-04-18 2015-04-20 Humanized anti-tf-antigen antibodies

Publications (3)

Publication Number Publication Date
BR112016024214A2 BR112016024214A2 (pt) 2018-01-23
BR112016024214B1 BR112016024214B1 (pt) 2023-11-14
BR112016024214B8 true BR112016024214B8 (pt) 2023-12-26

Family

ID=54324717

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024214A BR112016024214B8 (pt) 2014-04-18 2015-04-20 Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal

Country Status (12)

Country Link
US (1) US11130821B2 (pt)
EP (2) EP3797793A1 (pt)
JP (1) JP6740135B2 (pt)
KR (1) KR102413809B1 (pt)
CN (1) CN106488774B (pt)
AU (1) AU2015247358B2 (pt)
BR (1) BR112016024214B8 (pt)
CA (1) CA2943681A1 (pt)
ES (1) ES2843546T3 (pt)
MX (2) MX2016013686A (pt)
RU (1) RU2699717C2 (pt)
WO (1) WO2015161311A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
CA3073414A1 (en) * 2017-09-22 2019-03-28 Immunogen, Inc. Separation of triple-light chain antibodies using cation exchange chromatography
CN112119098A (zh) * 2018-03-28 2020-12-22 田边三菱制药株式会社 cMET单克隆结合剂的药物缀合物及其用途
CN112601550B (zh) * 2018-05-30 2023-12-08 财团法人卫生研究院 抗-乙型淀粉样蛋白抗体及其用途
JP2022515223A (ja) 2018-12-21 2022-02-17 オーエスイー・イミュノセラピューティクス ヒトｐｄ－１に対する二機能性分子
ES2963700T3 (es) 2018-12-21 2024-04-01 Ose Immunotherapeutics Anticuerpo humanizado anti-PD-1 humana
EA202191763A1 (ru) 2018-12-21 2022-03-10 Озе Иммьюнотерапьютикс Бифункциональная молекула анти-pd-1/sirp
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260680A1 (en) * 2004-04-16 2005-11-24 Vanderbilt University Methods of diagnosing and treating autoimmune diseases
JP4904266B2 (ja) 2004-07-26 2012-03-28 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 抗−ｔｆ−抗原抗体の治療的使用
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
BRPI0708970A2 (pt) * 2006-03-21 2011-06-21 Wyeth Corp método para o tratamento de um sujeito com uma doença ou transtorno caracterizado por depósito amilóide de a-beta; método de inibição ou redução da acumulação de depósito amilóide de a-beta em um sujeito; método de inibição ou redução da neurodegeneração em um sujeito; e método de inibição ou redução do declìnio cognitivo, ou de melhora da cognição, em um sujeito
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
CN102791735B (zh) * 2009-10-16 2016-05-18 瑟维尔实验室 抗前胃泌素的单克隆抗体及其用途
EP2347769A1 (en) * 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
CA2832389A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
KR20210074395A (ko) * 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CN102796144A (zh) * 2012-08-22 2012-11-28 山东大学 Tf抗原及其类似物、和其化学酶法合成方法及其应用
US10023651B2 (en) * 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies

Also Published As

Publication number Publication date
AU2015247358A1 (en) 2016-11-10
MX2016013686A (es) 2017-03-31
EP3131581A2 (en) 2017-02-22
EP3131581B1 (en) 2020-09-23
ES2843546T3 (es) 2021-07-19
US11130821B2 (en) 2021-09-28
EP3797793A1 (en) 2021-03-31
RU2016143552A3 (pt) 2018-11-14
CN106488774B (zh) 2019-11-01
WO2015161311A3 (en) 2015-12-10
KR20170010356A (ko) 2017-01-31
US20180258182A1 (en) 2018-09-13
BR112016024214A2 (pt) 2018-01-23
BR112016024214B1 (pt) 2023-11-14
MX2021000439A (es) 2021-03-25
RU2699717C2 (ru) 2019-09-09
EP3131581A4 (en) 2018-02-21
CA2943681A1 (en) 2015-10-22
CN106488774A (zh) 2017-03-08
WO2015161311A2 (en) 2015-10-22
JP2017518260A (ja) 2017-07-06
AU2015247358B2 (en) 2020-02-27
JP6740135B2 (ja) 2020-08-12
KR102413809B1 (ko) 2022-06-28
RU2016143552A (ru) 2018-05-21

Similar Documents

Publication Publication Date Title
BR112016024214B8 (pt) Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
BR112018011336A2 (pt) anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
MX2021009151A (es) Anticuerpos y receptores de antigeno quimerico especificos para ror1.
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
PH12016501384B1 (en) Human antibodies to pd-l1
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
EA201891084A1 (ru) Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
CO7160115A2 (es) Proteinas de unión a antigeno que se unen a pd-l1
GT201700102A (es) Conjugados de anticuerpo-fármaco
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
UA116772C2 (uk) Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47
EA201590671A1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
AR092612A1 (es) Anticuerpos anti-cd3, moleculas de union a antigeno biespecificas que se unen a cd3 y cd20, y usos de los mismos
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
BR112012028764A2 (pt) anticor-pos antifgfr2
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
PE20151893A1 (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
CL2021002008A1 (es) Proteinas de unión de antígeno del receptor gamma anti-il2.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/04/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2758 DE 14/11/2023, QUANTO AO ITEM (73) ENDERECO DO TITULAR.